OncoCyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the lung cancer care continuum, announced that it has entered into an agreement to acquire, through a subsidiary, all of the outstanding capital stock of privately-held Insight Genetics, Inc. (IG), which has a history of impactful discoveries in the areas of lung and breast cancer.
Read the full article: OncoCyte Announces Definitive Agreement to Acquire Insight Genetics //
Source: https://www.globenewswire.com/news-release/2020/01/10/1969124/0/en/Oncocyte-Announces-Definitive-Agreement-to-Acquire-Insight-Genetics.html